Tectonic Therapeutic (TECX) Current Deferred Revenue (2019 - 2022)

Tectonic Therapeutic (TECX) has reported Current Deferred Revenue for 4 consecutive years, with $51000.0 the latest figure, recorded in Q3 2022.

• In Q3 2022, Current Deferred Revenue fell 80.83% year-over-year to $51000.0; the TTM figure through Sep 2022 stood at $51000.0 (down 80.83% YoY), while the FY2021 annual figure was $262000.0, up 9.62% from the prior year.
• Current Deferred Revenue eased to $51000.0 in Q3 2022 per TECX's latest filing, from $183000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $266000.0 in Q3 2021 and bottomed at $51000.0 in Q3 2022.
• Historically, Current Deferred Revenue has averaged $215200.0 across 4 years, with a median of $227500.0 in 2020.
• Annual changes were most pronounced in 2021 — Current Deferred Revenue grew 23.15% — and 2022, when it plunged 80.83%.
• Tectonic Therapeutic's Current Deferred Revenue stood at $214000.0 in 2019, then increased by 11.68% to $239000.0 in 2020, then grew by 9.62% to $262000.0 in 2021, then sank by 80.53% to $51000.0 in 2022.
• Business Quant data shows TECX's Current Deferred Revenue at $51000.0 in Q3 2022, $183000.0 in Q2 2022, and $214000.0 in Q1 2022.